News Releases
Jun 8 2005
Peregrine Pharmaceuticals to Present at Rodman and Renshaw Techvest 2nd Annual Security & Connectivity Investor Conference
Jun 1 2005
Clinical Data Published in Neurosurgery Shows Peregrine Pharmaceuticals' Cotara(R) Holds Promise for Treating Brain Cancer
May 31 2005
Peregrine Pharmaceuticals Receives FDA Clearance to Initiate Tarvacin(TM) Anti-Viral Clinical Trial
May 16 2005
Data Published in Cancer Research Shows That Tarvacin(TM) Equivalent Plus Docetaxel Inhibits Breast Tumor Growth by 93%
May 5 2005
Peregrine Pharmaceuticals Submits Tarvacin(TM) Anti-Viral Investigational New Drug Application
Apr 26 2005
Peregrine Pharmaceuticals' Presentation Time at Investors Conference Changed to 10:50 a.m. EDT on April 28
Apr 22 2005
Peregrine Pharmaceuticals to Present at Wall Street Reporter Investors Conference
Apr 20 2005
Peregrine Pharmaceutical's Tarvacin(TM) Effective in Imaging Prostate Cancer
Apr 19 2005
Vascular Targeting Agent Effectively Inhibits Prostate Cancer Growth and Metastasis
Apr 18 2005
Tarvacin(TM) Equivalent (3G4) Plus Radiation Reduces Lung Tumor Growth By Over 95%